The Eliminating Kickbacks in Recovery Act (“EKRA”) was enacted in 2018 in an effort to address fraud occurring in substance use disorder (“SUD”) treatment. EKRA prohibits paying, receiving, or soliciting remuneration in return for patient referrals to laboratories, recovery homes, and clinical treatment facilities.[1] Under EKRA, clinical treatment facilities are defined broadly to include, “a…
For the past few years, healthcare professionals have faced unprecedented challenges, which have been exacerbated by the COVID-19 pandemic. A recent survey revealed that one of the top drivers for nurses leaving their current positions was the emotional toll of the job.[1] Conditions such as understaffing can lead to additional stress for physicians and other…
Concurrent with the Covid-19 Public Health Emergency (“PHE”), the Arizona Health Care Cost Containment System (“AHCCCS”) modified requirements related to member enrollment and provider revalidation. Following the Consolidated Appropriations Act of December 2022, Medicaid is decreasing specific additional funding made available during the PHE. As a result, AHCCCS has returned to the regular renewal process…
In July 2021, President Biden issued an Executive Order encouraging the Federal Trade Commission (“FTC”) to consider exercising its rulemaking authority to “curtail the unfair use of non-compete clauses and other clauses or agreements that may unfairly limit worker mobility.”[1] On January 5, 2023, the FTC issued a press release stating that non-competes in employment…
The materials provided in this website are for informational purposes only and are not for the purpose of providing legal advice. Transmission of information from the ML website is not intended to create, and its receipt by you does not create an attorney-client relationship with ML or any of its individual attorneys or personnel.
If you elect to communicate with anyone at ML through this website, or otherwise, in connection with a matter for which we do not already represent you, your communication can not be treated as privileged or confidential. Do not transmit any information about any matter (and particularly not information you regard as confidential) that may involve you until ML has agreed to represent you, and you have received confirmation of that fact in the form of a written engagement letter.